Pregnancy: part of life in chronic myelogenous leukemia

References

• Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94:S241–S247.
   PubMed Web of Science ®Google Scholar
• Malhotra P, Varma S. Chronic myeloid leukaemia in India. Lancet. 2007;370:1127
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29:1336–1343.
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26:185–192.
   PubMed Web of Science ®Google Scholar
• Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol. 2015;94:S167–S176.
   PubMed Web of Science ®Google Scholar
• Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015;35:1–11.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, Perrotti AP, et al. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6:e2014028
   PubMedGoogle Scholar
• Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol. 2009;22:455–474.
   PubMed Web of Science ®Google Scholar
• Nurmio M, Toppari J, Zaman F, et al. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl. 2007;30:366–376. Discussion 376.
   PubMedGoogle Scholar
• Schultheis B, Nijmeijer BA, Yin H, et al. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 2012;36:271–274.
   PubMed Web of Science ®Google Scholar
• Mariani S, Basciani S, Fabbri A, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril. 2011;95:1120 e1115–e1127.
   Web of Science ®Google Scholar
• Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351:2134–2135.
   PubMed Web of Science ®Google Scholar
• Zamah AM, Mauro MJ, Druker BJ, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011;16:1422–1427.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40:21–25.
   PubMed Web of Science ®Google Scholar
• Ault P, Kantarjian H, O’Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24:1204–1208.
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol. 2007;137:374–375.
   PubMed Web of Science ®Google Scholar
• Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res. 2008;32:519–520.
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Ault P, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood. 2008;112:3230.
   Web of Science ®Google Scholar
• Gentile M, Guido M, Lucia E, et al. Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma. 2014;55:709–710.
   PubMed Web of Science ®Google Scholar
• Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–5508.
   PubMed Web of Science ®Google Scholar
• He K, Lago MW, Iyer RA, et al. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos. 2008;36:2564–2570.
   PubMed Web of Science ®Google Scholar
• Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012;23:754–757.
   PubMed Web of Science ®Google Scholar
• Conchon M, Sanabani SS, Bendit I, et al. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol. 2009;2:42.
   PubMed Web of Science ®Google Scholar
• Orlandi EM, Elena C, Zibellini S. Chronic-phase chronic myeloid leukemia: not always a reassuring diagnosis. Leuk Res Rep. 2015;4:45–46.
   PubMedGoogle Scholar
• Santorsola D, Abruzzese E. Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib: a case report and a review. Mediterr J Hematol Infect Dis. 2015;7:e2015020
   PubMed Web of Science ®Google Scholar
• Kroll T, Ames MB, Pruett JA, et al. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma. 2010;51:1751–1753.
   PubMed Web of Science ®Google Scholar
• Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280:169–175.
   PubMed Web of Science ®Google Scholar
• Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27:241–243.
   PubMed Web of Science ®Google Scholar
• Kronenberger R, Schleyer E, Bornhauser M, et al. Imatinib in breast milk. Ann Hematol. 2009;88:1265–1266.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49:3242–3246.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Chelysheva E, Turkina A, Polushkina E, et al. Introduction of a treatment approach for chronic myeloid leukemia and pregnancy considering leukemic burden and pregnancy terms. Blood. 2015;126:5144–5144.
   Web of Science ®Google Scholar
• National Toxicology P. NTP Monograph: Developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. NTP Monogr. 2013:i-214.
   Google Scholar
• Kantarjian HM, Smith TL, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The leukemia service. Ann Intern Med. 1995;122:254–261.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074–3081.
   PubMed Web of Science ®Google Scholar
• Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica. 2008;93:770–774.
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511–2521.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423–431.
   PubMed Web of Science ®Google Scholar
• Lipton JH, Khoroshko N, Golenkov A, et al. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. 2007;48:497–505.
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Minakami H, Koshizuka S, et al. Administration of interferon-alpha during pregnancy: effects on fetus. J Perinat Med. 2000;28:372–376.
   PubMed Web of Science ®Google Scholar
• Yazdani Brojeni P, Matok I, Garcia Bournissen F, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33:265–268.
   PubMed Web of Science ®Google Scholar
• Baer MR, Ozer H, Foon KA. Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol. 1992;81:167–169.
   PubMed Web of Science ®Google Scholar
• Vianelli N, Gugliotta L, Tura S, et al. Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythemia. Blood. 1994;83:874–875.
   PubMed Web of Science ®Google Scholar
• Crump M, Wang XH, Sermer M, et al. Successful pregnancy and delivery during alpha-interferon therapy for chronic myeloid leukemia. Am J Hematol. 1992;40:238–239.
   PubMed Web of Science ®Google Scholar
• Lipton JH, Derzko CM, Curtis J. Alpha-interferon and pregnancy in a patient with CML. Hematol Oncol. 1996;14:119–122.
   PubMed Web of Science ®Google Scholar
• Kuroiwa M, Gondo H, Ashida K, et al. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy. Am J Hematol. 1998;59:101–102.
   PubMed Web of Science ®Google Scholar
• Mubarak AA, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002;69:115–118.
   PubMed Web of Science ®Google Scholar
• Al Bahar S, Pandita R, Nath SV. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynaecol Obstet. 2004;85:281–282.
   PubMed Web of Science ®Google Scholar
• Mesquita MM, Pestana A, Mota A. Successful pregnancy occurring with interferon-alpha therapy in chronic myeloid leukemia. Acta Obstet Gynecol Scand. 2005;84:300–301.
   PubMed Web of Science ®Google Scholar
• Regierer AC, Schulz CO, Kuehnhardt D, et al. Interferon-alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol. 2006;81:149–150.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Tarsa M, Herbst KD, et al. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res. 2011;37:1731–1733.
   PubMed Web of Science ®Google Scholar
• Conchon M, Sanabani SS, Serpa M, et al. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010;2010:136252.
   PubMedGoogle Scholar
• Saleh AJ, Alhejazi A, Ahmed SO, et al. Leukemia during pregnancy: long term follow up of 32 cases from a single institution. Hematol Oncol Stem Cell Ther. 2014;7:63–68.
   PubMedGoogle Scholar
• Ellis M, Mills AK. Successful maintenance of molecular remission in chronic myelogenous leukaemia during pregnancy with transition from imatinib to pegylated interferon. Intern Med J. 2015;45:358–359.
   PubMed Web of Science ®Google Scholar
• Woo GH, Katayama K, Bak EJ, et al. Effects of prenatal hydroxyurea-treatment on mouse offspring. Exp Toxicol Pathol. 2004;56:1–7.
   PubMed Web of Science ®Google Scholar
• Patel M, Dukes IA, Hull JC. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. Am J Obstet Gynecol. 1991;165:565–566.
   PubMed Web of Science ®Google Scholar
• Tertian G, Tchernia G, Papiernik E, et al. Hydroxyurea and pregnancy. Am J Obstet Gynecol. 1992;166:1868
   PubMed Web of Science ®Google Scholar
• Delmer A, Rio B, Bauduer F, et al. Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br J Haematol. 1992;82:783–784.
   PubMed Web of Science ®Google Scholar
• Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol. 1993;85:203–204.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, McCann SR. The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy. Clin Lab Haematol. 1993;15:63–65.
   PubMedGoogle Scholar
• Celiloglu M, Altunyurt S, Undar B. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. Acta Obstet Gynecol Scand. 2000;79:803–804.
   PubMed Web of Science ®Google Scholar
• Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001;15:1309–1311.
   PubMed Web of Science ®Google Scholar
• Fadilah SA, Ahmad-Zailani H, Soon-Keng C, et al. Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia. 2002;16:1202–1203.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390–1397.
   PubMed Web of Science ®Google Scholar
• Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101:1046–1051.
   PubMed Web of Science ®Google Scholar
• Broccia G, Casula P, Andria M. Chronic myelocytic leukemia in pregnancy: report of a case treated with leukapheresis. Tumori. 1984;70:371–374.
   PubMed Web of Science ®Google Scholar
• Fitzgerald D, Rowe JM, Heal J. Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am J Hematol. 1986;22:213–218.
   PubMed Web of Science ®Google Scholar
• Bazarbashi MS, Smith MR, Karanes C, et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol. 1991;38:235–237.
   PubMed Web of Science ®Google Scholar
• Yellu M, Pinkard S, Ghose A, et al. CML in pregnancy: a case report using leukapheresis and literature review. Transfus Apher Sci. 2015;53:289–292.
   PubMed Web of Science ®Google Scholar